Notice of Iran-related Disclosure Filed Pursuant to Section 13(r)(3) of the Exchange Act (irannotice)

 

	AstraZeneca PLC
	1 Francis Crick Avenue
	Cambridge Biomedical Campus
	Cambridge, CB2 0AA
	United Kingdom
	T: [phone]
	astrazeneca.com

 

U.S. Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

 

February 16, 2021

 

Re:             Notice of disclosure filed in Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act

 

Ladies and Gentlemen,

 

Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that AstraZeneca PLC has made disclosure pursuant to those provisions in its Annual Report on Form 20-F for the year ended December 31, 2020, which was filed with the Securities and Exchange Commission on February, 16 2021. The disclosure can be found under the heading “Item 4.B Business Overview—Disclosures Under the Iran Threat Reduction and Syria Human Rights Act of 2012” in the Annual Report on Form 20-F.

 

	AstraZeneca PLC
	Registered in England No. 2723534
	Registered office: 1 Francis Crick Avenue
	Cambridge Biomedical Campus
	Cambridge, CB2 0AA
	United Kingdom

 

---

 

Respectfully submitted,

 

 

/s/  A C N Kemp
A C N Kemp
Authorized Signatory
AstraZeneca PLC

 

	AstraZeneca PLC
	Registered in England No. 2723534
	Registered office: 1 Francis Crick Avenue
	Cambridge Biomedical Campus
	Cambridge, CB2 0AA
	United Kingdom

 

2

---